Bio-tech Firm Transcell Biologics nets 'Undisclosed amount' from Quantiphi & IAN Group
Quantiphi and IAN Group, both based in Boston, have invested an undisclosed sum in the biotech company Transcell Biologics.
The financial returns will be utilized for growing the client base and execution of Digital Animal Replacement Technology - DART as an enterprise solution for the worldwide bio and drug industry, Transcell Biologics said in a public statement.
Transcell Biologics, founded in 2009 by Subadra Dravida, focuses on increasing the yield of stem cells while maintaining pluripotency and functionality.
The company also offers a proprietary process and has expanded its range of applications for stem cell technologies. As per the Hyderabad-based organization, DART gives creature free testing techniques, combining human MicroPhysiological Frameworks (hMPS) innovation with artificial intelligence/ML implanted in silico stage designs to smooth out and computerize the bioassay processes delivering measurably consistent reports.
The solution is intended to effectively test safety and efficacy concerns regarding human-use drugs and vaccines. Transcell Biologics says that execution of DART has gotten some forward momentum in Indian business sectors, with biopharmaceutical organizations embracing its undertaking arrangement in their high-influence programs.
The company intends to increase its clientele in Japan, Europe, and the United States. Transcell Biologics is a creative biotech organization with consistent disclosure and interaction advancement as its focal subject to convey extraordinary troublesome immature microorganism-based answers for treat persistent and weakening infections that have in any case no choices accessible to make do.
Among the organization's milestone developments is the development of a novel proprietary process for boosting the therapeutic stem cell yield that likewise keeps up with the local pluripotent properties and innate functionality.
The business has grown from being solely a biotech company focused on research and development to becoming more diverse based on the intended uses of stem cell technologies.
The financial returns will be utilized for growing the client base and execution of Digital Animal Replacement Technology - DART as an enterprise solution for the worldwide bio and drug industry, Transcell Biologics said in a public statement.
Transcell Biologics, founded in 2009 by Subadra Dravida, focuses on increasing the yield of stem cells while maintaining pluripotency and functionality.
The company also offers a proprietary process and has expanded its range of applications for stem cell technologies. As per the Hyderabad-based organization, DART gives creature free testing techniques, combining human MicroPhysiological Frameworks (hMPS) innovation with artificial intelligence/ML implanted in silico stage designs to smooth out and computerize the bioassay processes delivering measurably consistent reports.
The solution is intended to effectively test safety and efficacy concerns regarding human-use drugs and vaccines. Transcell Biologics says that execution of DART has gotten some forward momentum in Indian business sectors, with biopharmaceutical organizations embracing its undertaking arrangement in their high-influence programs.
The company intends to increase its clientele in Japan, Europe, and the United States. Transcell Biologics is a creative biotech organization with consistent disclosure and interaction advancement as its focal subject to convey extraordinary troublesome immature microorganism-based answers for treat persistent and weakening infections that have in any case no choices accessible to make do.
Among the organization's milestone developments is the development of a novel proprietary process for boosting the therapeutic stem cell yield that likewise keeps up with the local pluripotent properties and innate functionality.
The business has grown from being solely a biotech company focused on research and development to becoming more diverse based on the intended uses of stem cell technologies.
.jpg "Varolyn Healthcare : Transforming Patient Care with Technology, Compassion, & Innovation")
